Director, Stem Cell Transplantation
Professor of Pediatrics, University of Pennsylvania School of Medicine
- Department: Pediatrics
- Division: Oncology
- Primary Address:
The Children's Hospital of Philadelphia
Oncology Division, Blood & Marrow Transplant Section
3400 Civic Center Boulevard Rm 8583
Philadelphia, PA 19104
Philadelphia, PA 19104
- (215) 590-2255
Allogeneic hematopoietic stem cell transplant
- Professor of Pediatrics at the Children's Hospital of Philadelphia (2004 – present)
- Associate Professor of Pediatrics at the Children's Hospital of Philadelphia (1995 – 2004)
- Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia (1991 – 1995)
- Assistant Professor of Pediatrics, University of Pennsylvania School of Medicine (1988 – 1991)
- M.D., University of Cincinnati (1980)
- B.A., Magna cum laude, University of Pennsylvania (1976)
As the director of the Children's Hospital Blood and Marrow Transplant (BMT) Program, I care for patients who will not be cured without a BMT. I also am involved in clinical research to improve outcomes and decrease risks for our transplant patients.
Our bone marrow transplantation program at The Children's Hospital of Philadelphia is one of the largest and oldest pediatric bone marrow transplant programs in the U.S., with more than 1,200 transplants performed. Our program provides the unique combination of comprehensive patient treatment, multidisciplinary teamwork, innovative research and family support. We have 11 beds in HEPA-filtered rooms in a special HEPA-filtered unit which includes a playroom and family lounge. Our physicians, radiation oncologists, nurse practitioners, donor search coordinator, social worker, nutritionists and child life specialists all work together to provide comprehensive care for each patient.
At Children's Hospital, we are expert in everything related to blood and marrow transplants. We have the ability to collect autologous (self) hematopoietic stem cells from very small children for use in high dose chemotherapy protocols. We have expertise in allogeneic transplants, with matched related donors, unrelated donors and cord blood.
We have various clinical studies open. Our research efforts are directed toward providing better outcomes for children who receive bone marrow transplantation. We have developed special protocols to reduce the risks of complications from graft vs. host disease (GVHD) with an unrelated or partially matched related donor, which gives us the ability to use donors other institutions may not be able to use.
Translational research forms an important part of our program. A drug, sirolimus, was found to be effective in killing lymphoid leukemia in the lab of one of our physicians. This drug was added post transplant to patients with leukemia post transplant to improve outcomes. This pilot study was then taken to the Children's Oncology Group, and is now an important randomized protocol which may improve leukemia free survival. We participate with the University of Pennsylvania's Abramson Cancer Center, and studies have been done to show that donor cells activated by a special process and then given to the patient with relapsed leukemia or lymphoma may have a potent anti-cancer effect. These studies are being expanded.
Our program is accredited by the Foundation for Accreditation of Cell Therapy (FACT). All three components -- clinical, cell collection and stem cell laboratory -- are accredited. FACT accreditation is an extremely rigorous process, and there are few pediatric centers that have all three components on site.
- Kitazono Hammell Mary T, Bunin Nancy, Edgar J Christopher, Jaramillo Diego. Paraphyseal changes on bone-age studies predict risk of delayed radiation-associated skeletal complications following total body irradiation. Pediatric radiology. Vol 43(9) . 2013 Sep:1152-8.
- Oshrine Benjamin R, Li Yimei, Teachey David T, Heimall Jennifer, Barrett David M, Bunin Nancy. Immunologic recovery in children after alternative donor allogeneic transplantation for hematologic malignancies: comparison of recipients of partially T-cell depleted peripheral blood stem cells and umbilical cord blood. Biology of blood and marrow transplantation. 2013 Aug.
- Goyal Rakesh K, Han Kelong, Wall Donna A, Pulsipher Michael A, Bunin Nancy, Grupp Stephan A, Mada Sripal R, Venkataramanan Raman. Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. Biology of blood and marrow transplantation. Vol 19(4) . 2013 Apr:569-75.
- Seif A E, Naranjo A, Baker D L, Bunin N J, Kletzel M, Kretschmar C S, Maris J M, McGrady P W, von Allmen D, Cohn S L, London W B, Park J R, Diller L R, Grupp S A. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone marrow transplantation. Vol 48(7) . 2013 Jan:947-52.
- Heimall Jennifer, Keller Michael, Saltzman Rushani, Bunin Nancy, McDonald-McGinn Donna, Zakai Elaine, de Villartay Jean-Pierre, Moshous Despina, Ariue Barbara, McCarthy Elizabeth A, Devlin Blythe H, Parikh Suhag, Buckley Rebecca H, Markert M Louise. Diagnosis of 22q11.2 deletion syndrome and artemis deficiency in two children with T-B-NK+ immunodeficiency.. Journal of clinical immunology. Vol 32(5) . 2012 Oct:1141-4.
- Aplenc R, Pasquini MC, Zhang, MJ, Zbu X, McCarthy PL, Ho VT, Cooke, KR, Sung L, Bunin, NJ. Effects of body mass index (BMI) in children undergoing allogeneic bone marrow transplant (BMT) for hematologic malignancies. Biology Blood & Marrow Transplant. 2012 Feb.
- Bunin N, Small T, Szabolcs P, Scott Baker K, Pulsipher MA, Torgerson T. NCI, NHLBI/PBMTC Nov 16, 2011. First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation. Persistent Immune Deficiency in Pediatric Transplant Survivors. Biol Blood Marrow Transplant. 2011 Nov:[Epub ahead of print].
- Nemecek ER, Ellis K, He W, Bunin NJ, Bajwa RS, Cheerva A, Cairo MS, Dvorak C, Duval M, Davies S, Eapen M, Gross TG, Hussein AA, Macmillan ML, Mehta PA, Pulsipher MA, Seber A, Woolfrey AE, Frangoul HA, Carpenter PA.. Outcome of Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation for Childhood Acute Lymphoblastic Leukemia in Third Remission. Biol Blood Marrow Transplant. Vol 17(12) . 2011 Dec:1833-1840.
- Dinardo L, Brown V, Perez E, Bunin N, Sullivan KE.. A single-center study of hematopoietic stem cell transplantation for primary immune deficiencies (PIDD). Pediatr Transplant. 2011 Nov.
- Baker KS, Bhatia S, Bunin N, Nieder M, Dvorak CC, Sung L, Sanders JE, Kurtzberg J, Pulsipher MA. Late effects after pediatric hematopoietic cell transplantation: State of the science, future directions. Biol Blood Marrow Transplant. Biol Blood Marrow Transplant. Vol 17(10) . 2011 Oct:1424-1427.